<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Tehran Heart Cent</journal-id><journal-id journal-id-type="iso-abbrev">J Tehran Heart Cent</journal-id><journal-id journal-id-type="publisher-id">JTHC</journal-id><journal-id journal-id-type="pmc">JTHC</journal-id><journal-title-group><journal-title>The Journal of Tehran University Heart Center</journal-title></journal-title-group><issn pub-type="ppub">1735-5370</issn><issn pub-type="epub">2008-2371</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25870629</article-id><article-id pub-id-type="pmc">4393834</article-id><article-id pub-id-type="publisher-id">jthc-9-120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of the Effectiveness of Continuous versus Intermittent Cefazolin for the Prevention of Infection after Off-Pump Coronary Artery Bypass Graft</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Forouzannia</surname><given-names>Seyed Khalil</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karimi-Bondarabadi</surname><given-names>Ali Akbar</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref><xref ref-type="corresp" rid="C1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bagherinasab</surname><given-names>Mostafa</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sarebanhassanabadi</surname><given-names>Mohammadtaghi</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib></contrib-group><aff id="AFF1"><label>1</label>Yazd Cardiovascular Research Center, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</aff><aff id="AFF2"><label>2</label>Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</aff><author-notes><corresp id="C1"><label>*</label><bold>Corresponding Author: Ali Akbar Karimi-Bondarabadi,</bold> Shahid Sadoughi University of Medical Sciences, Afshar Hospital, Jomhouri Blvd. Yazd, Iran. Tel: +98 9132736519. Fax: +98 351 5253335. E-mail: <email>aliakbarkarimi90@yahoo.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>03</day><month>7</month><year>2014</year></pub-date><volume>9</volume><issue>3</issue><fpage>120</fpage><lpage>123</lpage><history><date date-type="received"><day>05</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright&#x000a9; 2014 Tehran Heart Center, Tehran University of Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Background:</title><p>Surgical site infection is known as a common complication after cardiac surgery, and Cefazolin is the best prophylactic antibiotic to prevent this complication. The goal of this study was to evaluate the effect of continuous and intermittent Cefazolin for the prevention of superficial surgical site infection following off-pump coronary artery bypass (OPCAB).</p></sec><sec><title>Methods:</title><p>This prospective randomized clinical trial study was conducted on 141 patients candidated for OPCAB and divided into two groups. This study was performed between February 2011 and February 2012 in the Iranian city of Yazd. Patients in both groups received 2 g of Cefazolin as a starting dose and at 30 minutes before incision. Definition of surgical site infections was according to the Centers for Disease Control and Prevention Criteria (CDC-criteria). In the continuous infusion group (n = 74), 3 g of Cefazolin was infused over a 24-hour period after surgery. In the intermittent group (n = 67), 1 g of Cefazolin was administered at 3, 11, and 19 hours after the starting dose. Hyperlipidemia, diabetes, hypertension, smoking, history of heart disease, and incidences of superficial infection were compared between the two groups. Duration of follow- up was 4 weeks.</p></sec><sec><title>Results:</title><p>The mean age of the patients was 60.49 &#x000b1; 10.63 years. The patients were 30.5% female and 69.5% male. There were no significant differences in age, body surface area, duration of operation, number of distal grafts, number of proximal grafts, and duration of hospital stay before heart surgery between two groups. The incidence of infection in intermittent group was (7.5%) and in continuous groups was (2.7%). There was no significant difference in the incidence of infection between the two groups (p value = 0.26).</p></sec><sec><title>Conclusion:</title><p>Our findings in this study showed no significant differences between continuous and intermittent Cefazolin for the prevention of superficial surgical site infections after OPCAB.</p></sec></abstract><kwd-group><kwd>Cefazolin</kwd><kwd>Infection</kwd><kwd>Coronary artery bypass, off -pump</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cardiac surgery is known as an invasive and complex operation. Patients candidated for off-pump coronary artery bypass (OPCAB) are at risk of surgical site infection.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Infection after cardiac surgery is mostly related to sternotomy and vein graft harvesting site incisions.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Reported incidence rate of postoperative infection in cardiac surgery varies from 7% to 18%, and deep sternal wound infection has a reported incidence rate of 1% to 3%.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> These complications can cause mortality rates of up to 30%. Prophylactic antibiotics are recommended in cardiac surgery because of high mortality in patients with infections. The benefit of prophylactic antibiotics in cardiovascular surgery has been shown in some studies.<sup><xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref></sup> Staphylococci are the most common organisms that exist in the vein harvesting site and chest wound infections.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Cefazolin is the mainstay of prophylaxis in cardiac surgery thanks to its low toxicity and extensive microbial coverage.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Today in cardiac surgery, Cefazolin is administered intermittently as an intravenous bolus with a dose of 1 - 2 g before anesthesia induction and repeated after the onset of cardiopulmonary bypass or at wound closure and then two to three doses every 8 hours.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Cefazolin has a short elimination half time.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Accordingly, in this study, Cefazolin was used as a continuous infusion in order to counteract this effect. It is clear that a continuous infusion of Cefazolin after a bolus dose can provide continuously higher serum levels of Cefazolin compared to a bolus injection.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> It is, therefore, expected that a continuous infusion can be more effective as a prophylactic antibiotic therapy in cardiac surgery. However, some studies have shown no differences between the continuous and intermittent methods for the prevention of superficial surgical site infection.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><p>The aim of the present study was to compare bolus and continuous prophylactic Cefazolin injections in OPCAB candidates.</p></sec><sec sec-type="methods"><title>Methods</title><p>This prospective randomized clinical trial study, performed between February 2011 and February 2012 in the Iranian city of Yazd, recruited 141 patients candidated for OPCAB. The study was approved by the Ethics Committee of the Cardiovascular Research Center of Shahid Sadoughi University of Medical Sciences. This study was approved by Iranian Registry of Clinical Trial with IRCT-code: 2014041917026N1. All patients gave informed consent to participate in this study. The study population was divided into two groups through simple randomization: continuous and intermittent groups. Both groups received the same anesthesia and perioperative management and received 2 g of Cefazolin as a starting dose 30 minutes before incision. In the continuous infusion group (n = 74), 3 g of Cefazolin was continuously infused over a 24-hour period. In the intermittent group (n = 67), 1 g of Cefazolin was administered at 3, 11, and 19 hours after the starting dose. Definition of surgical site infections was according to the Centers for Disease Control and Prevention criteria (CDC-criteria). In this study, the evaluation of infections was based on the superficial type of the surgical site infection. Patients with a history of antibiotic therapy during the 72-hour period before surgery, severe renal and liver failure, and pregnancy were excluded from the study. Duration of follow-up was 4 weeks. Data were analyzed using the chi-squared and t-tests.</p></sec><sec sec-type="results"><title>Results</title><p>This prospective randomized clinical trial was conducted on 141 patients at a mean age of 60.49 &#x000b1; 10.63 years. Demographic data are presented in <xref ref-type="table" rid="T1">Table 1</xref>. Hyperlipidemia, diabetes mellitus, hypertension, smoking, and history of heart disease had no statically significant differences between the two groups (<xref ref-type="table" rid="T1">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Characteristics of the two groups<xref ref-type="table-fn" rid="TFN1"><sup>*</sup></xref></p></caption><table frame="hsides" rules="none"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="1">Intermittent Group (n=67)</th><th valign="middle" align="center" rowspan="1" colspan="1">Continuous Group (n=74)</th><th valign="middle" align="center" rowspan="1" colspan="1">Total (n=141)</th><th valign="middle" align="center" rowspan="1" colspan="1">P value</th></tr><tr><th valign="middle" align="left" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (y)</td><td valign="top" align="center" rowspan="1" colspan="1">62.83&#x000b1;13.57</td><td valign="top" align="center" rowspan="1" colspan="1">58.15&#x000b1;12.14</td><td valign="top" align="center" rowspan="1" colspan="1">60.49&#x000b1;14.63</td><td valign="top" align="center" rowspan="1" colspan="1">0.923</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Gender</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Male</td><td valign="top" align="center" rowspan="1" colspan="1">41 (61.2)</td><td valign="top" align="center" rowspan="1" colspan="1">57 (77.1)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (69.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.051</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Female</td><td valign="top" align="center" rowspan="1" colspan="1">26 (38.8)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (22.9)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (30.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia</td><td valign="top" align="center" rowspan="1" colspan="1">42 (62.7)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (60.8)</td><td valign="top" align="center" rowspan="1" colspan="1">87 (61.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.819</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes</td><td valign="top" align="center" rowspan="1" colspan="1">40 (59.7)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (55.4)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (57.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.663</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="center" rowspan="1" colspan="1">34 (50.7)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (43.2)</td><td valign="top" align="center" rowspan="1" colspan="1">66 (46.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.373</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking</td><td valign="top" align="center" rowspan="1" colspan="1">45 (67.2)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (66.2)</td><td valign="top" align="center" rowspan="1" colspan="1">94 (66.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.905</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of heart disease</td><td valign="top" align="center" rowspan="1" colspan="1">38 (56.7)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (63.5)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (60.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.410</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Data are presented as mean&#x000b1;SD or n (%)</p></fn></table-wrap-foot></table-wrap><p>The t-test analysis revealed no significant differences in terms of age (p value = 0.9), body surface area (p value = 0.77), surgery time (p value = 0.7), number of distal grafts (p value = 0.14), number of proximal grafts (p value = 0.36), and bedding time before heart surgery (p value = 0.33) between the two groups. Also, there was no significant difference in the incidence rate of postoperative infection between the two groups (p value = 0.26) (<xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Incidence of infection between the two groups<xref ref-type="table-fn" rid="TFN2"><sup>*</sup></xref></p></caption><table frame="hsides" rules="none"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Superficial infection</th><th valign="middle" align="center" rowspan="1" colspan="1">Bolus (n=69)</th><th valign="middle" align="center" rowspan="1" colspan="1">Continuous (n=74)</th><th valign="middle" align="center" rowspan="1" colspan="1">Total</th><th valign="middle" align="center" rowspan="1" colspan="1">P value</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th><th valign="middle" align="center" rowspan="1" colspan="1"><hr/></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">62 (92.5)</td><td valign="top" align="center" rowspan="1" colspan="1">72 (97.3)</td><td valign="top" align="center" rowspan="1" colspan="1">134 (95.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.264</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">5 (7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>*</label><p>Data are presented as n (%)</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Surgical site infection is one of the most important complications after surgery and is known as a second most common cause of nosocomial infections.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Wound infection can even lead to an increased financial burden by prolonging hospitalization.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> Risk factors that increase the incidence of postoperative wound infection include obesity, diabetes mellitus, use of internal mammary artery graft, advanced age, male gender, chronic obstructive pulmonary disease, smoking, and preoperative hospital stay of more than 5 days.<sup><xref rid="B12" ref-type="bibr">12</xref></sup> Some studies have suggested that diabetes mellitus can contribute to a more severe surgical site infection.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> On the other hand, smoking is thought to exert no significant effect on the rate of surgical site infection.<sup><xref rid="B14" ref-type="bibr">14</xref></sup></p><p>Overall, it is clear that an effective prophylactic antibiotic should be an appropriate antibiotic with a peak blood level before skin incision and an adequate level during surgery and the early postoperative period.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Cefazolin has a time-dependent killing feature; this means that the maximal effect of this antibiotic requires exposure to antibiotic concentrations above the minimum inhibitory concentration (MIC) to have the maximum efficacy.</p><p>In a study conducted by Zanetti G et al.,<sup><xref rid="B16" ref-type="bibr">16</xref></sup> the results demonstrated that intermittent Cefazolin could reduce surgical site infection by more than 16% in patients with prolonged (more than 240 minutes) surgical procedures. Waltrip T et al.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> indicated that beta-lactam antibiotics, when infused continuously, might be more effective than intermittent dosing in perioperative prophylaxis against wound infection. Kasiakou SK et al.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> reported that there was no difference in mortality and nephrotoxicity between their two study groups of continuous and intermittent intravenous administration. A systematic review, performed by Roberts et al. <sup><xref rid="B19" ref-type="bibr">19</xref></sup> showed that a continuous infusion of beta-lactam antibiotics had no potency to change the mortality rate statistically. In our study, the mortality rate was zero. In the Roberts et al.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> study, a continuous infusion of beta-lactam antibiotics did not influence the status of clinical cure; the authors, however, suggested that a continuous infusion had the same effect as a higher dose of a bolus administration. Zeller V et al.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> demonstrated that the administration of a continuous infusion of Cefazolin to treat bone and joint infection was practical, efficient, safe, and available. Harbath S et al.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> concluded that prolonging prophylaxis for more than 48 hours did not reduce the incidence of surgical site infection in cardiac surgery but it could increase resistance to microorganisms. Douglas A et al.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> suggested that 2 g of bolus Cefazolin 30 minutes prior to surgical incision could provide acceptable plasma and interstitial fluid concentrations for microorganisms in patients candidated for abdominal aortic aneurysm open repair surgery. Finkelstein R et al.<sup><xref rid="B23" ref-type="bibr">23</xref></sup> indicated that Vancomycin and Cefazolin had similar effects for preventing surgical site infection in open heart surgery; nevertheless, the authors reported that the side effects of Vancomycin included hypotension and resistance to microorganisms. Consequently, in the present study, we chose to utilize Cefazolin as the best prophylactic antibiotic in cardiac surgery. In previous studies, no significant differences were found in terms of the length of hospital stay and intensive care unit stay between the continuous infusion and the bolus injection of beta-lactam antibiotics.<sup><xref rid="B24" ref-type="bibr">24</xref></sup> In a study by Admebri et al.,<sup><xref rid="B9" ref-type="bibr">9</xref></sup> no patient had developed surgical site infection at 30 days after surgery. Furthermore, the authors found that a continuous infusion of Cefazolin after bolus Cefazolin administration provided better Cefazolin serum levels without increased costs and higher total dose. In our study, 7 patients acquired infection; the difference between the two groups, however, did not constitute a statistical significance.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>In light of the findings of the present study, there seem to be no significant differences between continuous and intermittent infusions of Cefazolin for the prevention of superficial surgical site infection after OPCAB. Nonetheless, further studies with more patients and longer follow-up periods are recommended.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was approved and supported by Shahid Sadoughi University of Medical Sciences. The authors are indebted to all the physicians, nurses, and patients who participated in this research.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-Ayala</surname><given-names>M</given-names></name><name><surname>Nan</surname><given-names>DN</given-names></name><name><surname>Farinas-Alvarez</surname><given-names>C</given-names></name><name><surname>Revuelta</surname><given-names>JM</given-names></name><name><surname>Gonzalez-Macias</surname><given-names>J</given-names></name><name><surname>Farinas</surname><given-names>MC</given-names></name></person-group>
<article-title>Surgical site infection during hospitalization and after discharge in patients who have undergone cardiac surgery</article-title>. 
<source>Infect Control Hosp Epidemiol</source>
<year>2006</year>;
<volume>27</volume>:
<fpage>85</fpage>&#x02013;<lpage>88</lpage>.
<pub-id pub-id-type="pmid">16418996</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridderstolpe</surname><given-names>L</given-names></name><name><surname>Gill</surname><given-names>H</given-names></name><name><surname>Granfeldt</surname><given-names>H</given-names></name><name><surname>Ahlfeldt</surname><given-names>H</given-names></name><name><surname>Rutberg</surname><given-names>H</given-names></name></person-group>
<article-title>Superficial and deep sternal wound complications: incidence, risk factors and mortality</article-title>. 
<source>Eur J Cardiothorac Surg</source>
<year>2001</year>;
<volume>20</volume>:
<fpage>1168</fpage>&#x02013;<lpage>1175</lpage>.
<pub-id pub-id-type="pmid">11717023</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Austin</surname><given-names>TW</given-names></name><name><surname>Coles</surname><given-names>JC</given-names></name><name><surname>Burnett</surname><given-names>R</given-names></name><name><surname>Goldbach</surname><given-names>M</given-names></name></person-group>
<article-title>Aortocoronary bypass procedures and sternotomy infections: a study of antistaphylococcal prophylaxis</article-title>. 
<source>Can J Surg</source>
<year>1980</year>;
<volume>23</volume>:
<fpage>483</fpage>&#x02013;<lpage>485</lpage>.
<pub-id pub-id-type="pmid">6969109</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamayo</surname><given-names>E</given-names></name><name><surname>Gualis</surname><given-names>J</given-names></name><name><surname>Fl&#x000f3;rez</surname><given-names>S</given-names></name><name><surname>Castrodeza</surname><given-names>J</given-names></name><name><surname>Eiros Bouza</surname><given-names>JM</given-names></name><name><surname>Alvarez</surname><given-names>FJ</given-names></name></person-group>
<article-title>Comparative study of single-dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery</article-title>. 
<source>J Thorac Cardiovasc Surg</source>
<year>2008</year>;
<volume>136</volume>:
<fpage>1522</fpage>&#x02013;<lpage>1527</lpage>.
<pub-id pub-id-type="pmid">19114201</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carignan</surname><given-names>A</given-names></name><name><surname>Allard</surname><given-names>C</given-names></name><name><surname>Pepin</surname><given-names>J</given-names></name><name><surname>Cossette</surname><given-names>B</given-names></name><name><surname>Nault</surname><given-names>B</given-names></name><name><surname>Valiquette</surname><given-names>L</given-names></name></person-group>
<article-title>Risk of clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain</article-title>. 
<source>Clin Infect Dis</source>
<year>2008</year>;
<volume>46</volume>:
<fpage>1838</fpage>&#x02013;<lpage>1843</lpage>.
<pub-id pub-id-type="pmid">18462108</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scher</surname><given-names>KS</given-names></name></person-group>
<article-title>Studies on the duration of antibiotic administration for surgical prophylaxis</article-title>. 
<source>Am Surg</source>
<year>1997</year>;
<volume>63</volume>:
<fpage>59</fpage>&#x02013;<lpage>62</lpage>.
<pub-id pub-id-type="pmid">8985073</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Engelman</surname><given-names>RM</given-names></name><name><surname>Houck</surname><given-names>P</given-names></name><name><surname>Shahian</surname><given-names>DM</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name></person-group>
<article-title>The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery, part I: duration</article-title>. 
<source>Ann Thorac Surg</source>
<year>2006</year>;
<volume>81</volume>:
<fpage>397</fpage>&#x02013;<lpage>404</lpage>.
<pub-id pub-id-type="pmid">16368422</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moellering</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Swartz</surname><given-names>MN</given-names></name></person-group>
<article-title>Drug therapy: the newer cephalosporins</article-title>. 
<source>N Engl J Med</source>
<year>1976</year>;
<volume>294</volume>:
<fpage>24</fpage>&#x02013;<lpage>28</lpage>.
<pub-id pub-id-type="pmid">1105179</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adembri</surname><given-names>C</given-names></name><name><surname>Ristori</surname><given-names>R</given-names></name><name><surname>Chelazzi</surname><given-names>C</given-names></name><name><surname>Arrigucci</surname><given-names>S</given-names></name><name><surname>Cassetta</surname><given-names>MI</given-names></name><name><surname>Gaudio</surname><given-names>ARD</given-names></name><name><surname>Novelli</surname><given-names>A</given-names></name></person-group>
<article-title>Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters</article-title>. 
<source>J Thorac Cardiovasc Surg</source>
<year>2010</year>;
<volume>140</volume>:
<fpage>471</fpage>&#x02013;<lpage>475</lpage>.
<pub-id pub-id-type="pmid">20570290</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burke</surname><given-names>JP</given-names></name></person-group>
<article-title>Infection control - a problem for patient safety</article-title>. 
<source>N Engl J Med</source>
<year>2003</year>;
<volume>348</volume>:
<fpage>651</fpage>&#x02013;<lpage>656</lpage>.
<pub-id pub-id-type="pmid">12584377</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohammdzade</surname><given-names>MA</given-names></name><name><surname>Akbar</surname><given-names>MH</given-names></name><name><surname>Mohammdzade</surname><given-names>A</given-names></name></person-group>
<article-title>Complications of elective abdominal aortic aneurysm surgery</article-title>. 
<source>Acta Medica Iranica</source>
<year>2007</year>;
<volume>45</volume>:
<fpage>116</fpage>&#x02013;<lpage>120</lpage>.
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hollenbeak</surname><given-names>CS</given-names></name><name><surname>Murphy</surname><given-names>DM</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Woodward</surname><given-names>RS</given-names></name><name><surname>Dunagan</surname><given-names>WC</given-names></name><name><surname>Fraser</surname><given-names>VJ</given-names></name></person-group>
<article-title>The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery</article-title>. 
<source>Chest</source>
<year>2000</year>;
<volume>118</volume>:
<fpage>397</fpage>&#x02013;<lpage>402</lpage>.
<pub-id pub-id-type="pmid">10936131</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Ivanov</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>G</given-names></name><name><surname>Scully</surname><given-names>HE</given-names></name><name><surname>David</surname><given-names>TE</given-names></name></person-group>
<article-title>Deep sternal wound infection: risk factors and outcomes</article-title>. 
<source>Ann Thorac Surg</source>
<year>1998</year>;
<volume>65</volume>:
<fpage>1050</fpage>&#x02013;<lpage>1056</lpage>.
<pub-id pub-id-type="pmid">9564926</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vuorisalo</surname><given-names>S</given-names></name><name><surname>Haukipuro</surname><given-names>K</given-names></name><name><surname>Pokela</surname><given-names>R</given-names></name><name><surname>Syrj&#x000e4;l&#x000e4;</surname><given-names>H</given-names></name></person-group>
<article-title>Risk features for surgical-site infections in coronary artery bypass surgery</article-title>. 
<source>Infect Control Hosp Epidemiol</source>
<year>1998</year>;
<volume>19</volume>:
<fpage>240</fpage>&#x02013;<lpage>247</lpage>.
<pub-id pub-id-type="pmid">9605272</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engelman</surname><given-names>R</given-names></name><name><surname>Shahian</surname><given-names>D</given-names></name><name><surname>Shemin</surname><given-names>R</given-names></name><name><surname>Guy</surname><given-names>TS</given-names></name><name><surname>Bratzler</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>F</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><name><surname>Fernando</surname><given-names>H</given-names></name><name><surname>Bridges</surname><given-names>C</given-names></name><collab>Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons</collab></person-group>
<article-title>The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice</article-title>. 
<source>Ann Thorac Surg</source>
<year>2007</year>;
<volume>83</volume>:
<fpage>1569</fpage>&#x02013;<lpage>1576</lpage>.
<pub-id pub-id-type="pmid">17383396</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanetti </surname><given-names>G</given-names></name><name><surname>Giardina</surname><given-names>R</given-names></name><name><surname>Platt</surname><given-names>R</given-names></name></person-group>
<article-title>Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery</article-title>. 
<source>Emerg Infect Dis</source>
<year>2001</year>;
<volume>7</volume>:
<fpage>828</fpage>&#x02013;<lpage>831</lpage>.
<pub-id pub-id-type="pmid">11791504</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waltrip</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>V</given-names></name><name><surname>Farmer</surname><given-names>M</given-names></name><name><surname>Clayton</surname><given-names>S</given-names></name><name><surname>Myers</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Galandiuk</surname><given-names>S</given-names></name></person-group>
<article-title>A pilot study to determine the feasibility of continuous cefazolin infusion</article-title>. 
<source>Surg Infect (Larchmt)</source>
<year>2002</year>;
<volume>3</volume>:
<fpage>5</fpage>&#x02013;<lpage>9</lpage>.
<pub-id pub-id-type="pmid">12593694</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasiakou</surname><given-names>SK</given-names></name><name><surname>Sermaides</surname><given-names>GJ</given-names></name><name><surname>Michalopoulos</surname><given-names>A</given-names></name><name><surname>Soteriades</surname><given-names>ES</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name></person-group>
<article-title>Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials</article-title>. 
<source>Lancet Infect Dis</source>
<year>2005</year>;
<volume>5</volume>:
<fpage>581</fpage>&#x02013;<lpage>589</lpage>.
<pub-id pub-id-type="pmid">16122681</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Webb</surname><given-names>S</given-names></name><name><surname>Paterson</surname><given-names>D</given-names></name><name><surname>Ho</surname><given-names>KM</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name></person-group>
<article-title>A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics</article-title>. 
<source>Crit Care Med</source>
<year>2009</year>;
<volume>37</volume>:
<fpage>2071</fpage>&#x02013;<lpage>2078</lpage>.
<pub-id pub-id-type="pmid">19384201</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeller</surname><given-names>V</given-names></name><name><surname>Durand</surname><given-names>F</given-names></name><name><surname>Kitzis</surname><given-names>MD</given-names></name><name><surname>Lhotellier</surname><given-names>L</given-names></name><name><surname>Ziza</surname><given-names>JM</given-names></name><name><surname>Mamoudy</surname><given-names>P</given-names></name><name><surname>Desplaces</surname><given-names>N</given-names></name></person-group>
<article-title>Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations</article-title>. 
<source>Antimicrob Agents Chemother</source>
<year>2009</year>;
<volume>53</volume>:
<fpage>883</fpage>&#x02013;<lpage>887</lpage>.
<pub-id pub-id-type="pmid">19075069</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Samore</surname><given-names>MH</given-names></name><name><surname>Lichtenberg</surname><given-names>D</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name></person-group>
<article-title>Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance</article-title>. 
<source>Circulation</source>
<year>2000</year>;
<volume>27</volume>:
<fpage>2916</fpage>&#x02013;<lpage>2921</lpage>.
<pub-id pub-id-type="pmid">10869263</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Douglas</surname><given-names>A</given-names></name><name><surname>Udy</surname><given-names>AA</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Jarrett</surname><given-names>P</given-names></name><name><surname>Stuart</surname><given-names>J</given-names></name><name><surname>Lassig-Smith</surname><given-names>M</given-names></name><name><surname>Deans</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>MS</given-names></name><name><surname>Taraporewalla</surname><given-names>K</given-names></name><name><surname>Jenkins</surname><given-names>J</given-names></name><name><surname>Medley</surname><given-names>G</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name></person-group>
<article-title>Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery</article-title>. 
<source>Antimicrob Agents Chemother</source>
<year>2011</year>;
<volume>55</volume>:
<fpage>5238</fpage>&#x02013;<lpage>5242</lpage>.
<pub-id pub-id-type="pmid">21859939</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finkelstein</surname><given-names>R</given-names></name><name><surname>Rabino</surname><given-names>G</given-names></name><name><surname>Mashiah</surname><given-names>T</given-names></name><name><surname>Bar-El</surname><given-names>Y</given-names></name><name><surname>Adler</surname><given-names>Z</given-names></name><name><surname>Kertzman</surname><given-names>V</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Milo</surname><given-names>S</given-names></name></person-group>
<article-title>Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections</article-title>. 
<source>J Thorac Cardiovasc Surg</source>
<year>2002</year>;
<volume>123</volume>:
<fpage>326</fpage>&#x02013;<lpage>332</lpage>.
<pub-id pub-id-type="pmid">11828293</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohd Hafiz</surname><given-names>AA</given-names></name><name><surname>Staatz</surname><given-names>CE</given-names></name><name><surname>Kirkpatrick</surname><given-names>CM</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name></person-group>
<article-title>Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics</article-title>. 
<source>Minerva Anestesiol</source>
<year>2012</year>;
<volume>78</volume>:
<fpage>94</fpage>&#x02013;<lpage>104</lpage>.
<pub-id pub-id-type="pmid">21730935</pub-id></mixed-citation></ref></ref-list></back></article>